Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | BCL6 | P41182 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369409 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGBCL6 | |
| SCHEMBL22476049 | 0.83 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CB | |
| SCHEMBL19344355 | 0.83 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CB | |
| SCHEMBL29869061 | 0.83 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6985484 | 0.80 | PIK3CD (0.67) | PIK3CDPIK3CG | |
| SCHEMBL4566190 | 0.80 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL4174170 | 0.80 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL16585318 | 0.79 | PIK3CD (0.64) | PIK3CDMAPK14ADORA2AADORA1 | |
| SCHEMBL1313525 | 0.79 | PIK3CD (0.64) | PIK3CDMAPK14ADORA2AADORA1 | |
| SCHEMBL6986600 | 0.78 | PIK3CD (0.65) | PIK3CDPIK3CGBCL6MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | claimed |
| WO-2012009452-A1 | THE ROLE OF P13K P110 DELTA SIGNALING IN RETROVIRAL INFECTION AND REPLICATION | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-19 | — | — | WO | claimed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| EP-2139882-B1 | 3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | AMGEN INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-8329910-B2 | Quinolines for the treatment of PI3K-δ mediated diseases | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2010065923-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-06-10 | — | — | WO | disclosed |
| US-7705018-B2 | Substituted quinolines and their uses in treatment of inflammatory and related conditions | AMGEN INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705018-B2 | Substituted quinolines and their uses in treatment of inflammatory and related conditions | AMGEN INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705018-B2 | Substituted quinolines and their uses in treatment of inflammatory and related conditions | AMGEN INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-2139882-A1 | 3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE ( PI3K) INHIBITORS | Amgen Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20090023761-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023761-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023761-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2008118455-A1 | δ3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE ( PI3K) INHIBITORS | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023761-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | PIK3CD 16/4885PIK3CA 26/4885PIK3CB 35/4885 |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | TLR9, PIK3CD, PIK3R5 | PIK3CD 2/4885PIK3CA 8/4885PIK3CB 9/4885 |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | PIK3R5, PIK3R4, PIK3R3 | PIK3CD 6/4885PIK3CA 10/4885PIK3CB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.